

September 2025: Quarterly Activities Report

World-first clinical trial for the treatment of Binge Eating Disorder (BED) using TRP-8803 rapidly advances alongside broader clinical development pathway

- Regulatory approvals secured for Swinburne University to conduct global first BED trial, enabling product supply and trial commencement
- Patient recruitment for BED trial underway – First patient successfully enrolled with baseline assessments ongoing, ahead of initial dosing in the coming weeks
- Landmark biomarker collaboration with Professors Robin Carhart-Harris and Pedro Mediano to develop a proprietary EEG-based brain entropy platform for precision psychiatry and enhanced clinical outcomes
- Key clinical leadership strengthened with Professor David Castle (Consultant Medical Officer) appointed to assist in TRP-8803's formulation, psychiatric and trial capabilities
- \$2.6m R&D loan facility secured, providing non-dilutive funding to accelerate TRP-8803 development and advance additional clinical programs

Melbourne, Australia – Tryptamine Therapeutics Limited ('Tryp', 'TYP' or the 'Company') (ASX: TYP), a clinical-stage biotechnology company, is pleased to provide the following update on commercial and clinical activities undertaken during the three-month period ended 30 September 2025.

During the period, Tryp rapidly progressed its world first clinical trial to assess lead asset, TRP-8803 (IV-infused psilocin) for the treatment of Binge Eating Disorder ('BED'). Alongside this, the Company strengthened its management, secured non-dilutive funding and entered into a landmark agreement to advance brain entropy as a biomarker for use in clinical practice.

Management commentary

Tryp Chief Executive Officer, Jason Carroll, said: *"The September quarter marked one of the most important periods in Tryp's clinical development strategy, led by key initiatives to accelerate the world's first clinical trial of TRP-8803 in BED and several other milestones which consolidated our position as a leading drug development company.*

The receipt of regulatory approvals and commencement of patient recruitment for the BED trial represent significant achievements that position us at the forefront of psychedelic-assisted treatment innovation. We are particularly pleased to have delivered the first supply of TRP-8803 to Swinburne University, and enrolled the initial patient for the trial, ahead of first dosing in the coming weeks.

In parallel, we advanced our research leadership through a landmark collaboration with Professor Robin Carhart-Harris and Professor Pedro Mediano to develop a proprietary EEG-based biomarker platform — a transformative step and world first initiative towards precision psychiatry and regulatory-grade diagnostic tools. This work builds on our broader vision to pair TRP-8803's clinical utility with next-generation digital biomarkers that improve patient selection and treatment outcomes.

Operationally, the Company strengthened its clinical team which brings expertise in psychiatry and psychedelic-assisted therapies which will play a vital role as we advance TRP-8803 into multiple new indications.

With a world-first BED trial underway, a breakthrough biomarker development program, strengthened leadership, and a solid financial platform, Tryptamine is exceptionally well positioned to deliver on its strategic goals — redefining the treatment landscape for eating disorders and related mental health conditions.”

Operational overview:

Receipt of regulatory approvals for BED trial:

Work to advance the Company’s innovative BED trial was highlighted by Swinburne University’s receipt of a ‘Permit To Purchase Or Otherwise Obtain Poisons Or Other Controlled Substances For Industrial, Educational, Or Research Purposes’ from the Department of Health, Victoria. This approval allowed Tryp to commence supply of TRP-8803 to the university, ahead of first patient dosing later this quarter. Alongside this, the Company also successfully delivered first batches of TRP-8803 to the clinical trial site, ensuring ample trial supply.

The Company’s clinical trial will recruit a total of 12 patients suffering from BED, in two-six person cohorts. The cohorts will be administered two doses of TRP-8803, 14 days apart in a monitored setting and following psychotherapy and integration. Cohort 1 will receive a mid-range dose, while the second cohort will be administered a high-range dose.

The primary endpoint is to assess TRP-8803’s safety when administered twice in BED patients and during follow up through the 12-week period after first dose. Secondary and exploratory objectives include evaluating the ability of inducing the psychedelic state with TRP-8803 in a BED population and determining clinical activity and effects of TRP-8803 on the frequency of binge-eating episodes and other weight-related indicators in a BED population four weeks post second dosing. Tryp will also use results to explore TRP-8803’s utility on comorbidities that BED patients may suffer from, which will be used to finalise plans for future clinical development opportunities.

Patient recruitment initiatives for BED trial:

During the period, the Company began patient recruitment for its BED trial alongside Swinburne University. Commencement followed a series of activities, including governance approval, submission of relevant permits, completion of patient cohort protocols, staff recruitment, settlement of patient-centric collateral and TRP-8803 product manufacturing.

Swinburne has received a pleasing number of in-bound enquiries to date and patient screening is ongoing. Interested parties are encouraged to contact bed-iv@swin.edu.au for further information regarding potential participation in the study.

Post period end, the Company advised that it had successfully enrolled its first patient. This was a major achievement with enrolment following screening and face-to-face interviews. Following maiden patient enrolment, baseline assessment commenced, which includes taking measurements of binge eating behaviour, physical measurements such as Body Mass Index (BMI) and vital signs and comprehensive psychological and safety evaluations. Laboratory testing, including blood chemistry, haematology, serology and urinalysis, as well as neuropsychiatric assessments are being completed to provide a robust foundation for dosing in the weeks ahead.

For personal use only



A number of prospective patients are currently undergoing screening and further enrolments are expected shortly. Tryp is confident first dosing will take place in December, with high level results expected in Early Q1 CY26.

Landmark agreement to validate a novel EEG-based brain entropy biomarker for precision psychiatry:

During the period, Tryp entered into an exclusive biomarker development agreement with Professor Robin Carhart-Harris, Chair of TYP's Scientific Advisory Board and Professor Pedro Mediano of the Imperial College London to develop a proprietary electroencephalogram (EEG) based platform to support TRP-8803's clinical development.

The collaboration will see Professor Carhart-Harris and Professor Mediano work alongside Company personnel to develop a proprietary EEG-based biomarker platform, which leverages real-time cortical entropy to predict and optimise therapeutic outcomes before, during and after TRP-8803 treatment.

Work undertaken under the collaboration is expected to establish a new frontier in psychiatry and will be focused on building a platform that enables clinicians with the ability to identify patients that may have the best response to TRP-8803 intervention and how best to modulate dosing in real time to reach the optimal therapeutic or neuroplasticity window.

Establishing the agreement followed considerable research undertaken into trials of Central Nervous System (CNS) active treatments. This research showed CNS active treatments that use biomarkers have more than a 10-fold higher probability of achieving regulatory approval¹. Importantly, pricing of new drugs with companion biomarkers is typically higher than drugs without biomarkers and IP is significantly strengthened with the use of a companion diagnostic.

This program is to be based on Robin Carhart-Harris' Entropic Brain Hypothesis and will integrate machine learning algorithms with closed-loop EEG monitoring to define and modulate the ideal therapeutic zone for TRP-8803 infusion. The resulting diagnostic tool is expected to generate quantitative measures for mental health conditions, providing a new precedent in regulatory-grade physiological markers in psychiatry.

The Company is confident this agreement will build on its existing work associated with psychedelic-induced entry dynamics, which has shown promising connective network reorganisation in animal models, as well as EEG measurements from its Phase 1b trial which demonstrated higher spectral power at all EEG electrode points during a loading dose.

Key appointments to strengthen TRP-8803 clinical development:

During the quarter, Tryp strengthened its clinical development capabilities with two strategic appointments, prior to advancement of clinical trial and commercialisation initiatives.

Professor Marcel Mozafari was appointed as Senior Formulation Scientist and Professor David Castle was appointed as Consultant Medical Officer. A leading psychiatrist and Professor of Psychiatry at the University of Tasmania's Centre for Mental Health Service Innovation, Professor Castle is a recognised authority in mental health and psychedelic-assisted therapies, with over 900 published works and a strong background in clinical research and trial leadership.

The appointments expand Tryp's Australian-based operations team, enhancing its technical and clinical capability as preparations accelerate for the TRP-8803 BED trial with Swinburne University and planning for additional clinical trials progress.

Corporate:

\$2.6m in non-dilutive funding:

For personal use only

Tryp entered into an R&D loan facility with Rockford Equity Pty Ltd, which provided access to \$2.6m in non-dilutive funding to support FY26 R&D activities. The facility, which will be repaid from future R&D tax incentive receipts, enhances financial flexibility to fast-track clinical programs, including the Company's ongoing BED trial and other planned initiatives. The agreement strengthened Tryp's cash reserves, alongside pending \$0.8m FY24 and \$1.7M FY25 R&D tax rebates and will allow the Company to accelerate multiple milestones in the coming quarters.

Financial summary:

As at 30 September 2025, the Company held \$3.94m in cash, cash equivalents and funding facilities. Tryp expects an ATO R&D tax rebate in the coming months of ~\$0.8m for eligible FY24 expenses related to previous clinical trial initiatives, as well as a \$1.7m rebate from eligible FY25 expenses in the coming months.

In accordance with Listing Rule 4.7C, payments made to related parties and their associates included in item 6.1 of the Appendix 4C incorporates gross salaries, superannuation, fees and benefits to executive and non-executive directors.

Top 20 shareholders:

The Company's top 20 shareholders as at 30 September 2025 are set out in the below table:

Position	Holder Name	Holding	%
1	William Garner	157,900,000	11.36%
2	CITICORP NOMINEES PTY LIMITED	93,233,212	6.71%
3	Dr Daniel Tillett	62,000,000	4.46%
4	Jason Alan Carroll	52,300,000	3.76%
5	Netwealth Investments Limited <SUPER SERVICES A/C>	41,430,831	2.98%
6	Netwealth Investments Limited <WRAP SERVICES A/C>	36,078,419	2.60%
7	BNP Paribas Noms Pty Ltd	35,653,203	2.56%
8	Herwig Janssen	33,750,000	2.43%
9	Mr Phillip Richard Perry	23,900,000	1.72%
10	BNP Paribas Nominees Pty Ltd	22,030,191	1.58%
11	The Trust Company (Australia) Limited <SBF A/C>	20,210,313	1.45%
12	Mr James Kuo	18,367,000	1.32%
13	BNP Paribas Nominees Pty Ltd	17,035,197	1.23%
14	Mr Guosheng Chen	17,000,000	1.22%
15	Sobol Capital Pty Ltd <SOBOL CAPITAL A/C>	13,750,000	0.99%
16	Solequest Pty Ltd	12,000,000	0.86%
17	Altnia Holdings Pty Ltd <I Dixon Family A/C>	11,303,451	0.81%
18	Ajava Holdings Pty Ltd	11,000,000	0.79%
19	Grayhawk Capital Pty Ltd	10,750,000	0.77%
20	J P Morgan Nominees Australia Pty Limited	10,000,000	0.72%
	Total*	699,691,817	50.34%
	Total issued capital – selected security class(es)	1,390,048,588	100.00%

*Total is inclusive of unquoted escrowed shares

Use of funds:

In accordance with ASX Listing Rule 4.7C2, the Company provides the following (unaudited) update on its use of funds against amounts set out in the prospectus:

For personal use only

Indicative use of funds	Estimated total per prospectus	Actual cash outflows incurred (1 May 24 – 30 Jun 25)	Comment on material variances
R&D – Project Management & Analysis	\$2,485,000	\$1,568,267	
Completion of Phase 2a Fibromyalgia trial at University of Michigan	\$150,000	\$40,756	
Completion of Phase 2a irritable bowel syndrome trial at Mass General Hospital (Harvard)	\$200,000	-	
Completion of TRP-8803 dosing study in Australia including initial GMP manufacturing	\$1,050,000	\$3,392,715	<ul style="list-style-type: none"> Clinical program extended to include additional cohort; Purchase of additional EEG equipment to be used in TYP's ongoing clinical program which should reduce the cost of future clinical trials; Additional two subjects were included in the first cohort of the Phase 1b study; and The overall number of subjects treated in the study increased by over 50%.
	\$241,000	\$682,357	<ul style="list-style-type: none"> Manufacturing for the clinical study was completed within set budget. Additional activity undertaken relating to: <ul style="list-style-type: none"> - producing new API/raw materials; - formulation, including activity that will be used in development of the final formulation of the company's product.
Completion of Phase 2 trial in Binge Eating Disorder using TRP 8803	\$540,000	-	
Completion of Phase 2 trial in Chronic Pain Fibromyalgia using TRP 8803	\$375,000	-	
Technical staff	\$700,000	-	
Lead Manager/ Corporate Advisor fees	\$462,000	\$471,550	
Transaction and IPO costs	\$532,000	\$833,825	<ul style="list-style-type: none"> Capital raising costs associated with additional \$6M strategic placement
Working Capital for Corporate Uses	\$3,870,485	\$4,177,764	<ul style="list-style-type: none"> Increase in professional service fees and insurance costs relating to complexity of reverse takeover transaction.
Total funds	\$10,605,485	\$11,167,234	



This announcement has been authorised for release by the Board of Tryptamine Therapeutics Limited.

-ENDS-

Investor & media contact

Jason Carroll
Chief Executive Officer
Tryptamine Therapeutics Limited
jcarroll@trypttherapeutics.com

Henry Jordan
Six Degrees Investor Relations
+61 (0) 431 271 538
henry.jordan@sdir.com.au

About Tryptamine Therapeutics Limited

Tryp is a clinical-stage biotechnology company focused on developing proprietary, novel formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs. Tryp's lead program, TRP-8803, is a proprietary formulation of IV-infused psilocin (the active metabolite of psilocybin) with potential to alleviate numerous shortcomings of oral psilocybin including: significantly reducing the time to onset of the psychedelic state, controlling the depth and duration of the psychedelic experience, and reducing the overall duration of the intervention to a commercially feasible timeframe. The Company has completed a Phase 2a clinical trial for the treatment of binge eating disorder at the University of Florida, which demonstrated an average reduction in binge eating episodes of greater than 80%.

The Company also has also just completed a Phase 2a clinical trial for the treatment of fibromyalgia in collaboration with the University of Michigan and has initiated a Phase 2a clinical trial in collaboration with Massachusetts General Hospital for the treatment of abdominal pain and visceral tenderness in patients suffering from irritable bowel syndrome.

Each of the studies is utilising TRP-8802 (synthetic, oral psilocybin) to demonstrate clinical benefit in these indications. Where a positive clinical response is demonstrated, subsequent studies are expected to utilise TRP-8803 (IV-infused psilocin), that has the potential to further improve efficacy, safety, and patient experience.

For more information, please visit www.trypttherapeutics.com.

Register for updates

The Company encourages investors to register their details with Automic Group investor portal. This also provides shareholders with the opportunity to elect communication methods to electronic only. This can be done by:

- Go to investor.automic.com.au
- If you're an existing user, log in with your username and password
- If you're a new user, click 'register', select 'Tryptamine Therapeutics Limited'. Enter your Holding Number and postcode of the registered address on your holding. If your address is outside Australia, select the country. Follow the prompts to set up a username and password.
- Once you have created your account, you will need to update your communication method by clicking 'my details' under the 'profile' section of the investor portal account, then navigating to 'communication preferences' and select 'electronic only'

Risks associated with Psilocin

All medicines carry risks and specialist prescribers, such as registered psychiatrists are best placed to assess the suitability of a new medication against a patient's individual circumstances and medical history before proceeding. Adverse effects of psilocybin and similar compounds, such as psilocin, can include temporary increase in blood pressure and a raised heart rate. There may be some risk of psychosis in predisposed individuals. These effects of psilocybin and its derivatives are unlikely at low doses and in the treatment regimens used in psychedelic-assisted psychotherapy and appropriately managed in a controlled environment with direct medical supervision.

Forward-Looking Information

For personal use only

Certain information in this news release, constitutes forward looking information. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "targets", "expects" or "does not expect", "is expected", "an opportunity exists", "is positioned", "estimates", "intends", "assumes", "anticipates" or "does not anticipate" or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might", "will" or "will be taken", "occur" or "be achieved". In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management's expectations, estimates and projections regarding future events. Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by Tryp as of the date of this news release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward looking information, including but not limited to the factors described in greater detail in the "Risk Factors" section of Tryp's Replacement Prospectus available at www.asx.com.au These factors are not intended to represent a complete list of the factors that could affect Tryp; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this news release are made as of the date of this news release, and Tryp expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

ⁱ Wong, C. H., Siah, K. W. & Lo, A. W. Estimation of clinical trial success rates and related parameters. *Biostatistics* 20, 273–286 (2019).

For personal use only

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

TRYPTAMINE THERAPEUTICS LIMITED

ACN

163 765 991

Quarter ended ("current quarter")

30 September 2025

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (3 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	-	-
1.2 Payments for		
(a) research and development	(671)	(671)
(b) product manufacturing and operating costs	-	-
(c) advertising and marketing	(25)	(25)
(d) leased assets	-	-
(e) staff costs	(354)	(354)
(f) administration and corporate costs	(538)	(538)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	9	9
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	-	-
1.8 Other (provide details if material)	(119)	(119)
1.9 Net cash from / (used in) operating activities	(1,698)	(1,698)
2. Cash flows from investing activities		
2.1 Payments to acquire:		
(a) entities	-	-
(b) businesses	-	-
(c) property, plant and equipment	-	-
(d) investments	-	-
(e) intellectual property	-	-
(f) other non-current assets	-	-

For personal use only

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (3 months) \$A'000
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	Net cash from / (used in) investing activities	-	-
3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	27	27
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (repayment of lease liability)	-	-
	Other (bank guarantee and security deposit)	-	-
3.10	Net cash from / (used in) financing activities	27	27
4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	3,026	3,026
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(1,698)	(1,698)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	-	-

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (3 months) \$A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	27	27
4.5	Effect of movement in exchange rates on cash held	(7)	(7)
4.6	Cash and cash equivalents at end of period	1,348	1,348

5. Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts		Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	1,348	3,026
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	1,348	3,026

6. Payments to related parties of the entity and their associates

- 6.1 Aggregate amount of payments to related parties and their associates included in item 1
- 6.2 Aggregate amount of payments to related parties and their associates included in item 2

**Current quarter
\$A'000**

145

-

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments

The payments to directors or their associates in 6.1 include gross salaries, superannuation and fees and benefits to executive and non-executive directors.

7. Financing facilities

Note: the term "facility" includes all forms of financing arrangements available to the entity.

Add notes as necessary for an understanding of the sources of finance available to the entity.

	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
7.1 Loan facilities	2,600	-
7.2 Credit standby arrangements	-	-
7.3 Other (please specify)		
7.4 Total financing facilities	2,600	-

7.5 **Unused financing facilities available at quarter end** 2,600

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

R&D loan facility agreement with Rockford Equity Pty Ltd. The facility is secured against projected FY26 research and development activities and will be repaid from Tryp's future R&D Tax Incentive. The Company can elect to drawdown on the facility in \$500,000 tranches and will accrue interest at 16% per annum on the outstanding balance.

8. Estimated cash available for future operating activities	\$A'000
8.1 Net cash from / (used in) operating activities (Item 1.9)	(1,698)
8.2 Cash and cash equivalents at quarter end (Item 4.6)	1,348
8.3 Unused finance facilities available at quarter end (Item 7.5)	2,600
8.4 Total available funding (Item 8.2 + Item 8.3)	3,948
8.5 Estimated quarters of funding available (Item 8.4 divided by Item 8.1)	2.3

8.6 If Item 8.5 is less than 2 quarters, please provide answers to the following questions:

1. Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

N/A

2. Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

N/A

3. Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

N/A

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 31 October 2025
.....

Authorised by: Board of Directors
.....
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.